New treatment strategy for primary podocytopathies
Part of Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial is testing a new treatment approach for people with certain kidney diseases called podocytopathies (like FSGS and MCD). It may help if you have active disease, even after a kidney transplant, or if you have another type of kidney inflammation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have one of the following: primary podocytopathy (FSGS or MCD), secondary podocytopathy, other glomerulonephritis, or no history of kidney disease.
- Your kidney disease must be active (not in remission) or you have no kidney disease.
- You cannot be on dialysis or have a very low kidney function (eGFR less than 15).
- You must be willing and able to sign a consent form.
- No other medical condition that, in the doctor's opinion, would make it unsafe for you to participate.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study aims to improve how doctors diagnose nephrotic syndrome by using a personalized workflow. If you have nephrotic syndrome and are under 40 years old, this trial might help find the best treatment for your specific type.
This trial collects medical data and blood/urine samples from patients with minimal change disease or focal segmental glomerulosclerosis (FSGS) to better understand how the immune system damages kidney cells.
This trial tests whether SGLT2 inhibitors (a type of diabetes medicine) can help adults with primary nephrotic syndrome, a kidney disease that causes protein leakage and swelling. It aims to see if the drug can protect kidney function and reduce protein loss.
This study collects medical information and samples from patients with podocytopathy—a type of autoimmune kidney disease that causes protein leakage into urine. Researchers will analyze your medical records and any blood or kidney tissue samples you've already had to better understand the disease and find better treatments.
This study is a registry that collects medical information from people with nephrotic syndrome caused by FSGS or minimal change disease (MCD). It may help doctors better understand these conditions and improve future care, especially by tracking patients over time.
This study tests three experimental drugs (frexalimab, brivekimig, and rilzabrutinib) for people ages 16 to 75 with a type of kidney disease called primary FSGS or minimal change disease. The goal is to see if these drugs can reduce protein in your urine and help protect your kidneys.
Hear when a new Nephrotic Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.